Intestinal Mucosal Injury Reduction and Small Intestine Function Recovery

Reducing intestinal mucosal injury and promoting recovery of small intestine function" is not a single molecule, receptor, or conventional therapeutic target. Instead, it is a *biological process* or *therapeutic goal* involving multiple molecular mechanisms, cell types, and pathways. The repair of intestinal mucosal injury is orchestrated by a network of factors including intestinal stem cells (notably LGR5+ intestinal stem cells), growth factors (such as transforming growth factor β), cytokines (like IL-33), structural proteins (such as desmocollin-2), and various signaling pathways (including Wnt and Notch). These components collectively regulate phases of restitution, proliferation, differentiation, and reformation of the mucosal barrier[1][3][4][6]. Because this entry describes a **biological outcome rather than a discrete molecular entity**, it is not suitable as a canonical drug target under standard criteria.